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atriuretic Peptide-Guided
herapy for Heart Failure
eady for “Battle” or Too “Scarred”
y the Challenges of Trial Design?*
lan Maisel, MD
an Diego, California
hile natriuretic peptide (NP) testing has gained wide-
pread acceptance for the diagnosis and prognosis of heart
ailure (HF), as well as risk stratification across the spectrum
f cardiovascular disease, a major unanswered question is
hether titration of NP levels can be used to “personalize”
he treatment of patients with HF. On the surface, this
hould be a “no-brainer.” After all, on an individual level,
Ps are excellent surrogates for wedge pressure in volume-
verloaded HF patients; they correlate with New York
eart Association functional class and are better at risk
tratification than ejection fraction (1–4). In addition, HF
atients who demonstrate low or dropping NP levels over
ime have better outcomes than those who do not (5).
ecause HF mortality and readmissions remain unaccept-
bly high, we are clearly still in need of improved monitor-
ng tools. Therefore, it is necessary that we find and refine
uch tools. Biomarkers are a practical possibility; hence,
urther trials or NP-guided or other biomarkers are abso-
utely required.
See page 53
The BATTLESCARRED (NT-proBNP–Assisted Treat-
ent to Lessen Serial Cardiac Readmissions and Death)
rial, as reported by Lainchbury et al. (6) in this issue of the
ournal, is the latest and perhaps one of the best trials on
P-guided treatment of HF. In all, 364 outpatients with
F with N-terminal pro–B-type natriuretic peptide (NT-
roBNP) 150 pmol/l (roughly 1,300 pg/ml) were ran-
omly assigned to a usual care arm or to 1 of 2 aggressive
rms: NP guided or clinically guided. An HF score was
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bbott, Brahms, and Nanosphere.tilized to help guide the clinical arm, and NT-proBNP
evels were used for the NP-guided arm.
This study demonstrated a number of improved out-
omes out to 2 years with the NT-proBNP–guided strategy
mong patients 75 years of age. These included all-cause
ortality, survival or HF readmission, and days alive and
ot hospitalized with HF. These data have now held true
ut to 3 years of follow-up.
The recently published TIME-CHF (Trial of Intensi-
ed vs. Standard Medical Therapy in Elderly Patients
ith Congestive Heart Failure) study is the largest trial
o date to compare NT-proBNP–guided therapy with
ymptom-guided therapy in 499 outpatients with HF (7).
hat study concluded that the NT-proBNP–guided arm
id not improve overall clinical outcome. However, like the
ATTLESCARRED trial, the study did demonstrate that
ounger patients (between the ages of 60 and 75 years) had
higher survival free of hospitalization as compared with
ymptom-guided therapy.
That BNP has shown more effectiveness for patients
nder the age of 75 years but not for those over that age has
een looked upon skeptically, but that can be explained on
number of levels. Aging is associated with a number of
hanges in the cardiovascular system such as increased
ascular stiffness and myocardial stiffness, decreased beta-
drenergic responsiveness, impaired mitochondrial adeno-
ine triphosphatase production, and impaired endothelial
unction (8–10). The characteristics of elderly HF patients
re remarkably different from those of middle-aged HF
atients (11). In fact, limited data exist regarding medical
reatment of HF in elderly patients, as in most of the
andmark randomized controlled trials of HF the mean age
f enrolled patients is not representative of real-world HF
atients (12,13). Furthermore, across nearly every random-
zed control study of HF therapies, the benefits of widely
ccepted drugs for HF treatment were less evident (or
bsent) in the elderly. Moreover, HF therapies are under-
tilized for elderly patients (13). Finally, there is no treat-
ent that is proven effective for HF with preserved ejection
raction, which forms a large proportion of older HF
atients (14).
hy Do Clinical Trialists
coff at NP-Guided Studies?
henever I listen to the water-cooler discussions about
iomarker-guided clinical trials by the so-called “clinical
rialists,” skepticism is abundant. A failed primary end point
or a biomarker-guided trial should spell the end of that
iomarker the same way it does, they believe, for a cardiac
rug. Yet, the complexities of biomarker-guided trials are
ften orders of magnitude tougher than a phase-3 drug
tudy. Consider this: in a phase-3 drug study, the dose is
nown up front, the inclusion and exclusion criteria are
ften standard, the patient will receive drug or placebo, and
hile there is often debate over the primary end point, it
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uided study, however, difficult protocol decisions are un-
ertaken at every turn: what biomarker level you treat to,
hat medical regimen you use to achieve that goal, how you
andle the control group, and finally, what end points are
mportant. A cardiac drug should reduce cardiovascular
ortality, but should we hold a biomarker to that same
tandard? Wouldn’t it be enough to say that this would be
successful study if using a biomarker helped reduce
dmissions to the hospital, aided in adherence to guideline-
ased treatment, preserved renal function, and improved
uality of life? These are issues that need to be clarified as
linical trialists and biomarker experts morph into one
eing. Here are some proposed guidelines for running
P-guided trials.
. Population To Be Tested
1. Age 75 years of age with decreased systolic function.
2. Ischemic or nonischemic left ventricular systolic dys-
function.
3. Pre-randomization levels of 400 for BNP and 5,000 for
NT-proBNP or recently destabilized HF.
4. Randomization performed after the diuretic dose is
stabilized so that patients are at their “optivolemic” NP
level.
I. Testing Strategy
1. Acute HF. While dropping NP levels during hospital-
ization are clearly associated with better short-term
outcomes, and in fact many physicians routinely utilize
NP levels in the hospital to help obtain euvolemia, it is
remarkable that there has never been a randomized
inpatient NP-guided treatment study. An acute HF
NP-guided intervention trial should take place at the
time of hospital admission with decompensated HF and
continue to 30 days post-hospitalization. The goal
would clearly be to keep the patient decongested with
appropriate diuretics and vasodilator titration so as to
prevent early readmission.
2. Chronic heart failure. A recent randomized NP-guided
HF study from Sweden, presented at European Society
of Cardiology–Heart Failure in Nice, was supposed to
have both groups aim for the same drug regimen, one
trying to lower NP levels by 50%, on levels drawn every
30 days. The NP levels dropped only 10% in both
groups, and medication ended up the same across the
board. Is it any wonder the study was negative?
The following should be considered when formulating
esting strategies:
. Guideline versus NP guided. If we are ever going to
truly personalize outpatient HF treatments, we must be
willing to test whether an NP-guided treatment regimen
can personalize guideline-recommended treatments.
Some patients might go above recommended doses of
certain medications, such as spironolactone, or receive acombination of angiotensin-converting enzyme inhibi-
tors with angiotensin receptor blockers or hydralazine
and nitrates, whereas others may actually require lower
doses of certain medications. For instance, in my prac-
tice, a patient on a regimen of carvedilol 12.5 mg twice
a day who has a blood pressure of 90 mm Hg and a BNP
200 pg/ml will likely stay on that dose rather than be
titrated upward.
. Consider randomizing NP-guided versus control by
center rather than by patient in community settings.
As long as the centers are matched with regard to type
of patient, treating doctor (cardiologist versus primary
care), and medical regimen, you avoid the “learning
biases” inherent in single-center randomization. In
addition, one could make the case for using nonaca-
demic settings, in which HF specialty groups would
mitigate much of the benefit of NP guidance and,
furthermore, which do not represent real-world com-
munity practice.
. An NP-guided center should utilize the following:
a. Bedside or office NP assessment tools.
b. An algorithm that has pre-defined treatment goals. In
other words, in the euvolemic patient, angiotensin-
converting enzyme inhibitors, beta-blockers, and
aldosterone blockers would be titrated at least to
recommended guideline doses. After this, consid-
eration of digoxin and addition of an angiotensin
receptor blocker or hydralazine/nitrates could be
considered, as well as cardiac resynchronization
therapy if indications are met. Along with an
“obligatory treatment strategy” would also be the
ability to do one’s “best job,” namely, to still be a
physician and render rational clinical judgment.
c. NP sampling at frequent intervals (1 to 2 weeks), with
medication adjustments made based on those levels.
If the target has not been reached, a medication
change must be undertaken as long as blood pressure,
renal function, and potassium are under control.
d. Sampling of NP levels whenever there are symptoms
of worsening HF, with follow-up sampling as soon as
the condition is improved with treatment.
e. Some measure of renal function should be taken to
help interpret NP levels.
f. A clinical congestion score, to separate hypervolemic
decompensation from progression of disease.
g. Most importantly, the strategy should include some
measure of quality control to ensure that the physician
responds to an elevated NP concentration. Simply
saying, “I’m OK with the BNP value, because the
patient ‘looks OK’” is not acceptable, given what is
known about the prognostic value of NPs.
. Control or usual care group should:
a. Treat patients according to their usual clinical practice—
this would be a mirror of what goes on in clinical
practice.b. Have a copy of HF guidelines.
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December 29, 2009/January 5, 2010:61–4 Natriuretic Peptide-Guided Therapy for HFc. See patients no more frequently than what is deter-
mined the community standard (3-month intervals)
unless symptoms develop.
. What should the NP target level be? This is 1 of the
more perplexing issues in NP-guided studies. Do we
personalize a patient’s target NP value, and if so, how on
earth would we do this? A 50% decrease from hospital-
ization? There are no solid data here, but I would avoid
looking at relative changes after hospitalization, as the
discharge NP might not reflect the NP 2 weeks later
because diuretics still need adjusting. I believe we should
aim for the following: a sustained BNP level200 pg/ml
(NT-proBNP 1,000 pg/ml) with the following caveats:
a. Avoid symptomatic hypotension
b. Avoid renal insufficiency
A “time to target” NP study would be interesting, but
I think until the target values and treatment algorithms
are defined, that will be a difficult undertaking. One of
the odd things that has been seen in this area is that some
patients take months to achieve their optimal NP con-
centration, whereas others take only weeks to reach the
same value. Are these patients different?
. What should the end points be? This is the toughest
challenge of all, and has been the demise of a number of
potentially good therapies. A few statements can be made:
a. The primary end point will need to be either cardio-
vascular mortality or total mortality. One year would
be the minimal time for such a study.
b. Sample size needs to be appropriate. A recent sample
calculation proposed by Zannad (F. Zannad, personal
communication, June 2009) for a cluster randomization
of centers for an acute and post-acute HF trial includes:
• Deaths in the control group equal to 38%;
• An intraclass correlation of 0.05;
• It will be necessary to randomize 174 centers;
• Each including on average 15 patients;
• With 80% power at a 5% significance level;
• To detect reduction of mortality of 18%.
Total  2,400 patients
c. An alternative primary end point could be days alive
and not in the hospital with congestive heart failure.
In the study by Lainchbury et al. (6), NP-guided
therapy showed positive results among patients 75
years of age, out to 3 years of follow-up.
d. Secondary end points will be extremely important and
should take into account the following:
• Number of HF hospitalizations. It is my belief
that one of the major beneficial effects of successful
NP-guided treatment will be reduced hospitaliza-
tions, especially after physicians develop comfort
with NP-guided regiments.
• Number of episodes of destabilized HF not requir-
ing hospitalization. Many centers now manage
their patients who have mild destabilization with
outpatient therapies rather than admitting them—this is a very relevant sign of impending need for
inpatient hospitalization or worse.
• Surrogate markers:
i. Renal function—cystatin C, Ngal
ii. Subendocardial ischemia, necrosis—troponin
• Percent of patients who have dropped NP levels to
pre-selected number.
• Percent of patients who are below, at, or above
guideline-recommended therapy.
oward the Future
recent meta-analysis of the TIME-CHF, STARS-BNP
Plasma Brain Natriuretic Peptide-Guided Therapy to Im-
rove Outcome in Heart Failure), and STARBRIGHT
Strategies for Tailoring Advanced Heart Failure Regimens in
he Outpatient Setting: Brain Natriuretic Peptide Versus the
linical Congestion Score) trials, which included 918 patients,
ound that a strategy using NP levels to guide therapy resulted
n a significant reduction in all-cause mortality (15). Thus, it
ppears that while NP levels are not ready for prime time,
hanks to studies like BATTLESCARRED, the waters are
ertainly calmer. There is still a strong need for more trials,
ndividual peptide targets, more data on patients 75 years of
ge, an examination of some of the newer biomarkers such as
id region proANP and mid region proADM, and the
ossibility of using a combination of biomarkers that reflects
ardiac wall stress, ischemia, and renal function. Targeting the
bnormal biology of HF is crucial to reduce the considerable
isk we are seeing with this disease—at the end of the day, we
n cardiology must begin to embrace the concept of biologically
uided treatment for our patients with HF. Although caveats
xist, the BATTLESCARRED study points us in a direction
6). Future studies will need to continue down this path, which
s one that we must take.
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